Akeso's Ivonescimab Shows 30.8-Month Median Overall Survival, Topping Merck's Pembrolizumab

Akeso announced that its oncology immunotherapy ivonescimab achieved overall survival in a trial that exceeded that of Merck's pembrolizumab. Comparative data showed that ivonescimab extended median overall survival to 30.8 months, versus 22.6 months for pembrolizumab.

On September 14, 2026, Akeso's share price rose. As of 11:25 a. m. , Akeso traded at HK$95, up 5.2%, with turnover exceeding HK$1.07 billion. The stock reached an intraday high of HK$96.55, a gain of as much as 6.9%.